# Clinical signals do not settle TB-500 effects or long-term safety > TB-500 Effects: Clinical Signals, Safety, and Limits — Clinical signals do not establish TB-500 effects. Review anecdotal reports, adverse experiences, biological cautions, and evidence limits. **Evidence note / safety** Community reports are labeled as reports. Audited biological cautions are cited. The missing controlled blend or fragment data stays visible. ## Clinical context in plain English TB-500 is a seven-amino-acid fragment linked to thymosin beta-4 research. Community discussion focuses on recovery, mobility, soreness, wound healing, and occasional hair changes. Those claims do not come from controlled human trials of the fragment. Most published repair findings involve animals and often the full-length thymosin beta-4 protein. Community reports also include fatigue, injection-site reactions, headache, nausea, and mood changes. This page presents those themes without treating them as clinical outcomes. It then summarizes the signed corpus's safety cautions and cites the relevant studies: the lack of human fragment data, theoretical tumor and blood-vessel concerns, the difference between TB-500 and its parent protein, anti-doping consequences, and uncertainty around research-grade material. Several cautions remain theoretical because direct studies do not exist. The [clinical-status record](/research) provides the technical evidence; this page provides the accessible effects and safety layer. ## What people report These are effects reported by research-use communities — **anecdotal, not clinical evidence**. Frequency labels describe how often a theme appeared in the corpus sources; they are not measured rates and do not prove that the peptide caused the experience. **Reported benefits** - **Faster recovery from tendon, ligament and muscle injuries — very commonly reported.** The dominant community theme is a faster return from soft-tissue injury, with wide variation and no controlled human confirmation. - **Less joint pain and stiffness, better range of motion — frequently reported.** People often pair less aching with easier movement; the reports do not establish cause. - **Improved overall flexibility and mobility — frequently reported.** Everyday movement and training can feel easier in some accounts, but the effect has not been measured under study conditions. - **Feeling of reduced inflammation or 'calmed down' soreness — occasionally reported.** Some accounts describe less swelling or post-exercise soreness; no human fragment trial confirms an anti-inflammatory effect. - **Better wound and skin healing — occasionally reported.** Cuts, surgical sites, and irritated skin appear in occasional stories, while the aligned wound literature is mainly animal work on the parent protein. - **Hair regrowth or thicker hair — rarely reported.** Hair change is a minor, inconsistent signal often mixed with other interventions. **Reported adverse effects** - **Injection-site redness, swelling or aching — very commonly reported.** Local soreness, redness, or swelling is the most repeated adverse report. - **Temporary tiredness or lethargy — frequently reported.** Short-lived tiredness is one of the more consistent whole-body complaints. - **Head rush, lightheadedness or headache — occasionally reported.** Brief lightheadedness and headache appear less often than fatigue or local reactions. - **Brief flu-like feeling — occasionally reported.** A small group describes a short run-down or feverish feeling early in use. - **Nausea — rarely reported.** Nausea is an uncommon and usually mild community report. - **Heightened awareness of an existing injury — rarely reported.** Some people say an old injury feels more noticeable; this is a sensation, not proof of repair activity. - **Temporary low mood or mood changes — rarely reported.** Short-lived mood changes appear rarely, with no clinical evidence linking them to TB-500. ## Safety and cautions **Human safety in people is essentially unstudied.** No completed controlled human trial has tested the TB-500 heptapeptide, so its safety profile in people remains unknown. [13] [6] [13] [6] **Theoretical cancer / tumor-growth concern.** The tumor concern is theoretical but biologically specific: full-length thymosin beta-4 has links to cell migration, angiogenesis, and tumor progression in laboratory research. [21] [22] **Banned in competitive sport (WADA-prohibited).** TB-500 is prohibited in tested sport, and analytical methods can detect the peptide and its breakdown products. [13] [23] [13] **Reported benefits may overstate what the peptide actually does.** A long-term mouse study increased regenerating muscle fibers without improving strength, heart function, or fibrosis; a repair marker did not become a functional gain. [24] [24] **TB-500 is a fragment, not the full thymosin beta-4 protein.** TB-500 is the Ac-LKKTETQ fragment, not full-length thymosin beta-4. Applying whole-protein findings to the fragment is an unconfirmed extrapolation. [5] [23] [5] **Research-grade product quality is not guaranteed.** Unregulated research material can vary in identity, sequence, and purity, making both reactions and claimed results harder to interpret. [25] **Theoretical bleeding, surgery and clotting considerations.** **Theoretical caution.** Bleeding, surgery, and clotting concerns are theoretical. The corpus contains no direct human fragment study that measures those outcomes. **Theoretical caution in pregnancy, breastfeeding and the young.** **Theoretical caution.** Pregnancy, breastfeeding, and developmental cautions are also theoretical because cell movement and blood-vessel growth are basic developmental processes and no human safety data exist. --- A tabbed research binder on TB-500 and thymosin beta-4 — each evidence class filed behind its own divider and cited to source, the fragment kept apart from its parent protein, with no clinic behind the binder and nothing here dispensed or prescribed.